Biotech Values

[jq1234]

BMS' Apixaban Tentatively Scheduled For May 22 FDA Advisory Committee Meeting

FDA will review the company’s anti-clotting agent a day before looking at a new indication for J&J’s Xarelto in ACS.

http://www.elsevierbi.com/publications/rpm-report/first-take/2012/02/bms-apixaban-tentatively-scheduled-for-may-22-fda-advisory-committee-meeting